Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Blood (2025) 146 (Supplement 1): 366.

https://doi.org/10.1182/blood-2025-366

Published: 2025

Journal Articles

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V. Kostopoulos, Romanos Sklavenitis-Pistofidis, Febe Smits, Carmen Roncal, Michelle Aranha, David Zihala, Michaela Machu, Nikolaos Tsakirakis, Panagiotis Bakouros, Ourania Tsitsilonis, Eirini Solia, Cristina Moreno, Catarina Maia, Esperanza Martin-Sanchez, José J. Perez, Cristina Encinas, Rafael Rios Tamayo, Albert Oriol, María-Jesús Blanchard, Felipe de Arriba, Esther González García, Sunil Lakhwani, Anna Sureda Balarí, Valentin Cabanas Perianes, Fernando Escalante Barrigón, Estrella Carrillo-Cruz, Albert Pérez-Montaña, Enrique Ocio, Joan Bargay, Alberto Orfao, Tomas Jelinek, Irene Ghobrial, Tuna Mutis, Sonja Zweegman, Evangelos Terpos, Efstathios Kastritis, Joaquin Martinez-Lopez, Juan-Jose Lahuerta Palacios, Carlos Fernandez de Larrea, Laura Rosiñol, Joan Batista Blade Creixenti, Paula Rodriguez-Otero, María-Victoria Mateos, Jesus San-Miguel, Maria Teresa Cedena Romero, Noemí Puig, Bruno Paiva

Blood (2025) 146 (Supplement 1): 365.

https://doi.org/10.1182/blood-2025-365

Published: 2025

Journal Articles

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

Blood (2025) 146 (Supplement 1): 364.

https://doi.org/10.1182/blood-2025-364

Published: 2025

Journal Articles

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Blood (2025) 146 (Supplement 1): 494.

https://doi.org/10.1182/blood-2025-494

Published: 2025

Journal Articles

Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)

Blood (2025) 146 (Supplement 1): 493.

https://doi.org/10.1182/blood-2025-493

Published: 2025

Journal Articles

Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data

Blood (2025) 146 (Supplement 1): 1834.

https://doi.org/10.1182/blood-2025-1834

Published: 2025

Journal Articles

Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden

Blood (2025) 146 (Supplement 1): 3927.

https://doi.org/10.1182/blood-2025-3927

Published: 2025

Journal Articles

Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8‑color flow cytometry panel reveals substantial differences among products kinetics and persistence

Ondrej Venglar, Viera Hrabcakova, Ondrej Soucek, Kamila Kutejova, David Žihala, Jana Mihalyova, Michaela Hornakova, Tereza Sevcikova, Lucie Broskevicova, Lenka Janska Vojtkova, Marek Borsky, Jakub Radocha, Pavel Zak, Michael Doubek, Tomas Kalina, Roman Hajek, David Belada, Frantisek Folber, Tomas Jelinek

Blood (2025) 146 (Supplement 1): 5721.

https://doi.org/10.1182/blood-2025-5721

Published: 2025

Journal Articles

High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy

Blood (2025) 146 (Supplement 1): 5720.

https://doi.org/10.1182/blood-2025-5720

Published: 2025

Journal Articles

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Blood (2024) 144 (20): 2121–2135.

https://doi.org/10.1182/blood.2024024590

Published: 2024

Includes: Supplemental data

Journal Articles

Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 1934.

https://doi.org/10.1182/blood-2024-205481

Published: 2024

Journal Articles

Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma

Tomas Jelinek, Serafim Nenarokov, Tereza Sevcikova, Eva Radova, Ondrej Venglar, Veronika Kapustova, Lucie Broskevicova, Jan Vrana, Ludmila Muronova, Tereza Popkova, Jana Mihalyova, Hana Plonkova, Michal Simicek, Bachisio Ziccheddu, Benjamin Diamond, Francesco Maura, Ola Landgren, David Zihala, Roman Hájek

Blood (2024) 144 (Supplement 1): 3270.

https://doi.org/10.1182/blood-2024-206825

Published: 2024

Journal Articles

Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients

Ondrej Venglar, Eva Radova, David Zihala, Ivana Tvrda, Ludmila Muronova, Veronika Kapustova, Lucie Broskevicova, Jan Vrana, Tereza Popkova, Jana Mihalyova, Hana Plonkova, Tereza Sevcikova, Michal Kascak, Milan Navratil, Zdenek Koristek, Roman Hajek, Tomas Jelinek

Blood (2024) 144 (Supplement 1): 1962.

https://doi.org/10.1182/blood-2024-204692

Published: 2024

Journal Articles

A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma

Tereza Popkova, Jakub Radocha, Martin Stork, Jiří Minařík, Jan Straub, Alexandra Jungova, Petr Pavlicek, Tomas Jelinek, Vladimir Maisnar, Ludek Pour, Tomas Pika, František Sedlák, Jan Soukup, Hana Plonkova, Ludmila Muronova, Viera Sandecka, Petra Krhovska, David Zihala, Roman Hajek

Blood (2024) 144 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2024-211224

Published: 2024

Journal Articles

Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment

Blood (2024) 144 (Supplement 1): 1887.

https://doi.org/10.1182/blood-2024-206798

Published: 2024

Journal Articles

Pathogenesis of Extramedullary Multiple Myeloma: From Resistance to Identification of Novel Therapeutic Targets

Tomas Jelinek, David Zihala, Tereza Sevcikova, Veronika Kapustova, Hana Sahinbegovic, Anjana Anilkumar Sithara, Tereza Popkova, Hana Plonkova, Lucie Broskevicova, Jan Vrana, Vladimir Zidlik, Martin Havel, Zdenek Koristek, Juli R. Bago, Michal Simicek, Roman Hajek

Blood (2021) 138 (Supplement 1): 2680.

https://doi.org/10.1182/blood-2021-150876

Published: 2021

Journal Articles

Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia

Tomas Jelinek, Renata Bezděková, David Zihala, Tereza Sevcikova, Lenka Capkova, Petra Polackova, Martin Stork, Zdenka Knechtova, Ondrej Venglar, Artur Jurczyszyn, Jorge J. Castillo, Miroslav Penka, Jakub Radocha, Sabina Sevcikova, Ludek Pour, Lucie Rihova, Roman Hajek

Blood (2021) 138 (Supplement 1): 546.

https://doi.org/10.1182/blood-2021-151592

Published: 2021

Journal Articles

Effect of Daratumumab-Containing Induction on CD34+ Hematopoietic Stem Cells before Autologous Stem Cell Transplantation in Multiple Myeloma

Ondrej Venglar, Tereza Sevcikova, Anjana Anilkumar Sithara, Veronika Kapustova, Jan Vrana, David Zihala, Ludmila Muronova, Lucie Huvarova, Lucie Broskevicova, Michal Simicek, Zdenek Koristek, Roman Hajek, Tomas Jelinek

Blood (2021) 138 (Supplement 1): 2764.

https://doi.org/10.1182/blood-2021-150360

Published: 2021

Journal Articles

Identification of Molecular Mechanisms Responsible for the Development of Extramedullary Disease in Myeloma and Potential Novel Therapeutic Targets Using Transcriptomic and Exome Profiling

David Zihala, Tereza Sevcikova, Michal Simicek, Tereza Popkova, Hana Plonkova, Lucie Broskevicova, Jan Vrana, Juli R. Bago, Roman Hajek, Giovanni Stracquadanio, Tomas Jelinek

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-142300

Published: 2020

Journal Articles

Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients

Alexander Vdovin, Michal Durech, PhD, Tomas Jelinek, Tereza Sevcikova, PhD, Juli R. Bago, Matous Hrdinka, PhD, David Zihala, Renata Snaurova, Hana Sahinbegovic, Tereza Popkova, Ryszard Smolarczyk, PhD, Tomasz Cichon, PhD, Sebastian Giebel, MDPhD, Roman Hajek, MD PhD, Michal Simicek, PhD

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-140673

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)

Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data

Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden

Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8‑color flow cytometry panel reveals substantial differences among products kinetics and persistence

High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)

Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma

Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients

A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma

Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment

Pathogenesis of Extramedullary Multiple Myeloma: From Resistance to Identification of Novel Therapeutic Targets

Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia

Effect of Daratumumab-Containing Induction on CD34+ Hematopoietic Stem Cells before Autologous Stem Cell Transplantation in Multiple Myeloma

Identification of Molecular Mechanisms Responsible for the Development of Extramedullary Disease in Myeloma and Potential Novel Therapeutic Targets Using Transcriptomic and Exome Profiling

Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only